Profile | GDS2987 / hmm20906-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 8.7 | 30 |
GSM215244 | HMVEC_vehicle_rep2 | 8.8 | 23 |
GSM215253 | HMVEC_vehicle_rep3 | 17.8 | 50 |
GSM215254 | HMVEC_atorvastatin_rep1 | 23.9 | 52 |
GSM215282 | HMVEC_atorvastatin_rep3 | 10.4 | 24 |
GSM215344 | HMVEC_atorvastatin_rep2 | 7.9 | 20 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 18.7 | 35 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 10.5 | 21 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 89.2 | 73 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 41.7 | 53 |
GSM215298 | PASMC_vehicle_rep2 | 43.1 | 55 |
GSM215310 | PASMC_vehicle_rep3 | 41 | 54 |
GSM215311 | PASMC_atorvastatin_rep1 | 29.3 | 46 |
GSM215312 | PASMC_atorvastatin_rep2 | 23.8 | 36 |
GSM215313 | PASMC_atorvastatin_rep3 | 48.1 | 57 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 35.3 | 51 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 18.3 | 34 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 25 | 40 |
GSM215327 | PASMC_SLx2119_rep1 | 13.8 | 25 |
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 30.5 | 50 |
GSM215330 | Fibroblasts_vehicle_rep1 | 2.7 | 7 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 1.8 | 6 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 17.2 | 42 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 9.8 | 27 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 9.8 | 24 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 18.9 | 51 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 11.2 | 34 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 1.2 | 4 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 10.2 | 30 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 10.3 | 26 |